AMSBIO announces XerumFree™ - a new concept in cell culture that allows you to culture cells without the use of serum.XerumFree™ has been developed taking into account what is missing in traditional basal cell culture media to sustain growth of all cell types, which is a nutritional approach at the cellular level. Containing no animal or human derived material, XerumFree™ is a serum replacement for all cell culture practices that is chemically defined thereby avoiding lot-to-lot variations and eliminating the need for testing new batches of serum. Since XerumFree™ does not contain…
Detachin™ Cell Detachment Solution from AMSBIO is a high-performance alternative to Trypsin/EDTA for detaching adherent cells from in vitro growth vessels. Detachin™ provides rapid, gentle, and effective detachment of a wide variety of adherent cells, including primary cells, from all commercially available tissue culture plasticware.
Proven to provide a consistent, safe, and efficient method for cell detachment and dissociation, Detachin™ contains protease and collagenase activities in an isotonic, phosphate buffer solution with EDTA. It has been tested successfully on many different primary…
AMSBIO has established a comprehensive portfolio of knock-out cell lines and lysates generated with CRISPR/Cas9 technology.
Using CRISPR/Cas9 gene editing technology for the generation of knock-out cell lines and cell lysates ensures the development of useful tools to validate antibody specificity and elucidate gene function. Knock-out cell lines and cell lysates are widely agreed to be the best negative controls to quickly and confidently prove an antibody’s specificity for a target of interest and ensure reproducibility.
Generated in the most widely used HEK293T, HeLa, and A549…
AMSBIO is a leading supplier of gold, silver and platinum coated substrates for nanotechnology researchers looking to use these surfaces to characterize self-assembled monolayers using atomic force microscopy (AFM), or scanning tunneling microscopy (STM).
Gold, silver and platinum surfaces offer a clean, near atomically-flat surface that is ideal for applications in nanotechnology, such as studies on self-assembly, single-molecule imaging, nano- or micro-contact printing, DNA origami, or nanophotonics.
Deposited under high vacuum (10-8 Torr) with 99.999% purity noble metal…
AMSBIO offers an unmatched portfolio of over 2000 tissue microarrays (TMAs), one of the best sample formats for rapid detection of cellular localization of RNA and protein expression.Recently AMSBIO introduced US Food & Drug Administration (FDA) standard TMAs for human, mouse and rat to its portfolio. Designed in close conformance with FDA guidelines, this range meets the requirements for tissue cross-reactivity studies required for therapeutic and diagnostic antibody and antibody-like molecules validation. Each array slide features the FDA recommended list of normal tissue types in…
AMSBIO has added a new range of GCaMP calcium indicators (jGCaMP7b, jGCaMP7c, jGCaMP7f, jGCaMP7s) to their portfolio of ready-to-use adeno-associated virus (AAV) biosensor products. These viruses encoded biosensors are supplied ready for use for neural activity studies in vivo.
AAV Biosensors provide a snapshot of intracellular interactions, specifically active brain circuitry. Using fluorescent protein-based AAV biosensors allows permanent marking of active cells over short time scales, providing a window into the real-time biochemistry of living cells and whole organisms.…
While One Nucleus CEO Tony Jones attended the Future of Swedish & Danish Life Science 2019 at Medicon Village last week, Marks & Clerk had Norway covered by co-hosting and co-sponsoring the UT Conference in London. Simon Portman of Marks & Clerk Law gave a contracts training seminar for Norwegian tech companies and Matt Pinney of Marks & Clerk brought them up to speed on the patentability of AI.
LabKey, a US-based custom informatics solution provider, offering a freely-accessible, enterprise-quality, open source software platform to help research organisations solve their research data challenges.
In February 2016, LabKey opened its UK office, appointing Dr Jason Leadley, as its Director of European Operations. Relying heavily on engagements driven by the download and use of its open source, Community Edition of its core software platform, LabKey Server.
LabKey's most significant UK engagement is with Genomics England, on the pioneering 100,000 Genomes Project, where it is…
Kadans enters the UK life science market by acquiring from Imperial College ThinkSpace the B900 building located on the Babraham Research Campus (“BRC”) in Cambridge, adding to its Pan-European science park portfolio. The fully let property accommodates two companies (Abzena and Bicycle Therapeutics) active in the field of cancer and immunology therapeutics, forming a welcome addition to Kadans existing science partner network including tenants such as Genmab, Merus and MDxHealth.
The recently developed, high quality bio- and chemistry laboratory facility as well as BRC as a location is a…
Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced the appointment of Simon Sturge as its new CEO, effective May 1, 2019. Simon succeeds David Chiswell, who remains a scientific adviser to the Company.
“We are delighted that such an experienced leader as Simon will lead Kymab to its next stage of growth,” said Martin Nicklasson, Non-Executive Chair. “Led by Simon, Kymab will continue to progress its innovative portfolio of products through the clinic and to market, driving our strategy to…